PharmaLeaders Publish New Report on CRO

GlobalData’s Industry Dynamics Team is pleased to announce the publication of its new PharmaLeaders report entitled: Contract Research Organizations Benchmark Report: Financial Performance Benchmarking & Competitive Landscape Assessment of Leading CROs.

This report represents the Industry Dynamics Team’s first endeavor into covering the pharmaceutical outsourcing marketplace.

GlobalData’s Industry Analyst, and author of the research, Adam Dion explains:“The CRO Benchmark Report will be one of many reports the Industry Dynamics Team will publish related to the outsourcing marketplace as we expand our coverage across the pharmaceutical value-chain to include vendors that provide drug makers with strategic ancillary services.”

“Over time, these reports will cover contract manufacturers, API producers, cloud IT services, cold-chain transport, logistics and other reports related to the pharmaceutical outsourcing. We believe our coverage and analysis of these services will be essential to pharma and biotech clients as the need to develop strategic partnerships with third-party vendors has never been more important."

“The pharmaceutical industry is currently facing significant headwinds — the blockbuster era is over and drug development costs continue to skyrocket. To respond, industry executives are changing the way they approach virtually every aspect of their business, including how they can maximise their resources and, at the same time, enter into risk-sharing agreements with contractors to generate significant cost savings,” says Dion.

The CRO Benchmark Report applies GlobalData’s proprietary ranking methodology to compare the competitive positions of 11 leading CRO companies on 17 financial metrics. These companies are analysed based on financial performance, cost-containment, capital structure and firm utilisation to illustrate the different strategies these companies are using to gain a competitive advantage. In addition to the financial metrics, this report discusses trends impacting the CRO marketplace, along with partnering and acquisition activity, and operations strategy.

This report also provides a drill-down analysis of three service lines, and four geographies to examine each segment’s revenue and growth leaders. Lastly, this research provides GlobalData’s outlook on the CRO sector and each company’s future competitive position.

GlobalData’s Director of Industry Dynamics, Joshua Owide, explains how the analysis found in the PharmaLeaders series will help clients improve their understanding of the outsourcing marketplace and the positioning of leading players and emerging competition:“The ultimate goal of our PharmaLeaders report series is to distinguish those companies that are at the forefront in their sector, in terms of financial performance, commercial effectiveness, and corporate strategy, from those firms that are trailing behind. Our analysis explains what is driving this divergence which enables clients to formulate their own strategies and improve decision making.”

Owide says: “These reports provide invaluable insights into the environment in which companies operate in and the events that will impact their businesses in the future”.

GlobalData’s PharmaLeaders report series is targeted at both the scientific and investor communities. Clients that have leveraged these reports come from industry R&D and strategy teams, private equity and venture capital firms, and professional and financial services consultancies.

Companies Covered in this report: Accelovance, Accovion, AMRI, Aptuit, Asklep, BioRasi, Catalent, Charles River, Chiltern, Clinipace, ClinStar, CMIC, Covance, CromSource, DKSH, EPS Corporation, Frontage, Icon, INC Research, Novella Clinical, Novotech, Ockham, Octagon Research Solutions, Paragon Biomedical, Parexel, Patheon, Pharmaron, Pharm-Olam, PPD, PRA International, PSI, QPS, Quintiles, ReSearch Pharmaceutical Services, Synexus, Syngene, SynteractHCR, TFS International, and WuXi.